

Press Release



Red Arrow Therapeutics and ASKA Pharmaceutical Sign Joint Research Agreement on Novel Preeclampsia Treatment

TOKYO, March 18, 2024 – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter “ASKA”), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886, hereinafter “the Company”), and Red Arrow Therapeutics Inc. (Head Office: Boston, Massachusetts/ CEO: Takuya Miyazaki) announced today that they have signed a joint research agreement to develop a new treatment for preeclampsia using advanced nanotechnology. Please see the attached for details.

The impact of this matter on the business performance of the Company for FY2023 will be immaterial.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp

ASKA Pharmaceutical and Red Arrow Therapeutics Sign Joint Research Agreement on Novel Preeclampsia Treatment

TOKYO, March 18, 2024 – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo, Japan/ President, Representative Director: Sohta Yamaguchi) and Red Arrow Therapeutics Inc. (Head Office: Boston, Massachusetts/ CEO: Takuya Miyazaki) announced today that they have signed a joint research agreement to develop a new treatment for preeclampsia using advanced nanotechnology.

A Statement from Takuya Miyazaki, CEO of Red Arrow Therapeutics:

"Through this partnership with ASKA Pharmaceutical, we're excited to push the boundaries of nanomedicine and bring a novel solution to a disease with significant impact on pregnant women and babies, who are the cornerstones of our future. Our joint effort exemplifies the power of combining cutting-edge science with pharmaceutical expertise."

A Statement from Sohta Yamaguchi, President, Representative Director of ASKA Pharmaceutical:

"This alliance with Red Arrow, which is known for its innovative drug delivery technology, enhances our pursuit of novel treatments. Together, we're focused on making significant strides in maternal healthcare. As a leading company in the field of obstetrics and gynecology, we will strive to fulfill unmet medical needs."

Since its foundation in 1920, ASKA Pharmaceutical has contributed to patients' well-being, specializing in the fields of internal medicine, obstetrics and gynecology, and urology as a specialty pharma.

Established in 2021, Red Arrow Therapeutics aims to deliver the cutting-edge nanomedical technology developed by Professor Horacio Cabral from the University of Tokyo to patients in need.

By combining ASKA Pharmaceutical's extensive expertise with Red Arrow Therapeutics' pH-sensing drug delivery nanotechnology, the joint research agreement is anticipated to birth a groundbreaking approach to combat preeclampsia, a condition that presents significant risks during pregnancy.

About Red Arrow Therapeutics Inc.

Emerging from Cabral Lab at the University of Tokyo in 2021, Red Arrow Therapeutics Inc. develops pH-sensing nanomedicine drug delivery technologies for multiple therapeutic areas such as oncology. Headquartered in Boston, Massachusetts, the company is committed to realizing cutting-edge technology for patients worldwide.

URL: <https://redarrowtx.com/>

About ASKA Pharmaceutical Co., Ltd.

Since its foundation in 1920, ASKA has concentrated its management resources in three core areas of internal medicine, obstetrics and gynecology, and urology, based on its corporate philosophy: "Contribute toward the improvement of people's health and progress in medicine through the development of innovative products." Under the Medium-Term Management Plan 2025, ASKA has set a goal to "become a Total Healthcare Company with a Strong Foundation as a Specialty Pharma Company." As a leading company in the obstetrics and gynecology field, ASKA is committed to contributing to the resolution of women's health issues through its business activities.

URL: <https://www.aska-pharma.co.jp/english/>

Inquiries

Red Arrow Therapeutics Inc.

E-mail: rika@redarrowtx.com

ASKA Pharmaceutical Co., Ltd.

Corporate Planning Department

E-mail: kouhou@aska-pharma.co.jp